These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 21907085)
21. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]
22. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Lebel M; Chagniel L; Bureau G; Cyr M Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905 [TBL] [Abstract][Full Text] [Related]
23. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046 [TBL] [Abstract][Full Text] [Related]
24. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756 [TBL] [Abstract][Full Text] [Related]
28. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Crossman AR Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120 [TBL] [Abstract][Full Text] [Related]
29. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389 [TBL] [Abstract][Full Text] [Related]
31. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism]. Lhermitte F; Rosa A; Comoy E Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319 [TBL] [Abstract][Full Text] [Related]
32. The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Stocchi F Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S68-71. PubMed ID: 20083012 [TBL] [Abstract][Full Text] [Related]
33. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801 [TBL] [Abstract][Full Text] [Related]
35. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. Cenci MA; Lundblad M J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598 [TBL] [Abstract][Full Text] [Related]
36. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244 [TBL] [Abstract][Full Text] [Related]
37. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101 [TBL] [Abstract][Full Text] [Related]
38. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686 [TBL] [Abstract][Full Text] [Related]